FOXP3 and myeloid sarcoma: To shed light on this issue, a recent meta-analysis of 16 studies concluded that there was no significant difference in CD4+CD25+ T cells between MS patients and HCs, although the proportion of CD4+CD25+FoxP3+ Treg decreased in MS patients [19].